SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGraft Polymer PLC Regulatory News (GPL)

  • There is currently no data for GPL

R&D Supply Agreement Signed

30 Aug 2023 07:00

RNS Number : 7205K
Graft Polymer (UK) PLC
30 August 2023
 

 

 

For Immediate Release 30th August 2023

 

 

 

R&D and Supply agreement signed with Empresas Vilher, Mexico, endorses the global reach of Graft Polymer expertise in unique polymer product development

 

 

Graft Polymer (UK) plc (LSE:GPL) ('Graft' or the 'Company'), the specialty chemicals company offering modified Polymer solutions for refiners, compounders and processors announces the signing of a Research and Development (R&D) and Supply agreement with Empresas Vilher, S.A de C.V. ('Vilher'), a Mexican company that specialises in Wood Plastic Composite, Plastic Recycling, and High-Performance Compounds. The Company has been working with the technical team from Vilher for several months on a variety of modified polymer projects which has led to the execution of a formal 12-month R&D and Supply agreement.

Wood Plastic Composite ('WPC')

WPC is made from waste wood (fibres or sawdust) and new or recycled plastic, bonded together with a binding agent. Graft's GRAFTABOND product is leading the field in trials in the PP, PE, HIPS & TR polymer matrices. The global WPC market is projected to grow from US$6.4bn in 2022 to US$15.3bn by 2030, a CAGR of 11.5%. 1

Plastic Recycling

The use of recycled plastic in the construction industry (buildings and roads) is a large, growing and lucrative market. Recycled plastic is increasingly being used for roofing tiles, indoor insulation, PVC windows, bricks, fences, floor tiles, carpeting, ceiling tiles, etc. In order to activate the relevant polymer groups to improve the characteristics of the recycled plastic, different modified polymers are used. The Recycled Plastic market is projected to reach US$55.9bn by 2026, growing at a CAGR of 6.03%. 2

High-Performance Compounds

The global plastic compounding market size was US$52.74bn in 2018 is projected to reach US$87.11bn by 2026, exhibiting a CAGR of 6.5% 3 during the forecast period from 2019-2026. The plastic compounding market growth is driven by the rising use of these products in various industries, including automotive, packaging and electrical.

 

 

 

 

Graft CEO Victor Bolduev, said: "The constructive commercial relationship between Graft and Vilher continues to grow. The technical teams are working on some exciting projects together which will hopefully lead to firm supply orders for our newly commissioned facility in Borovnica, Slovenia."

 

Cesar Casillas, Managing Director of Vilher, added: "Graft's pioneering polymer technology makes them a natural partner for our work in the field of plastic recycling. Together, we have a great opportunity to develop groundbreaking products for large industries."

 

About Vilher

Empresas Vilher, S.A. de C.V., is a Mexican company, founded in 1990 by two chemical engineers, in Guadalajara, Jalisco. For the plastics industry, Vilher, in alliance with 2 other companies (Gea and Noverek), create Innecsus Group and together they develop and offer ecological and sustainable solutions.

Graft and Vilher will be attending Plastimagen Mexico, the pioneering industry event for the transformation of plastic, from 7 to 10 November, 2023, at Centro Citibanamex in Mexico City, booth 2754.

 

For further information, visit www.graftpolymer.com,follow on Twitter @PolymerLtd or contact:

 

Graft Polymer (UK) Plc

Roby Zomer, Non-Executive Chairman Via Flagstaff

Yifat Steuer, CFO

 

Turner Pope Investments Tel:+44 (0) 20 3657 0050

James Pope

Andy Thacker

 

Flagstaff Strategic and Investor Communications Tel + 44 (0) 207 129 1474

Tim Thompson graftpolymer@flagstaffcomms.com

Mark Edwards

Alison Allfrey

 

 

 

 

 

 

About Graft Polymer

Graft Polymer is a London Stock Exchange listed company (GPL.L) with a cutting-edge, cash-flow positive, research and development (R&D) and manufacturing facility based in Slovenia which has already introduced more than 50 products to the market. The core business of the Group comprises polymer modification and drug delivery system developments. The Group has developed a proprietary set of polymer modification technologies which uses recycled raw materials and a closed loop system to reduce waste. Graft Polymer's technology can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.

Graft Polymer has three divisions: polymer modification; IP for Bio/Pharma applications including a drug delivery system (Graft Bio); and the Group's food supplement division. A significant milestone was reached in May 2022 when the Slovenian manufacturing facility was granted a Hazard Analysis and Critical Control Point (HACCP) Certificate. The HACCP Certificate allows it to enter the lucrative Business-to-Consumer market and commercialise its IP for bio/pharma applications, developing active pharmaceutical ingredients and drug delivery platforms for use in the food supplement market, thereby introducing a further revenue stream to its business.

Environment, Social and Governance is at the forefront of the Group's strategy and the facility in Slovenia has been granted ISO 14001 accreditation in recognition of the environmental management systems in place to reduce waste. Graft Polymer only uses REACH and ROHS certificated raw materials instead of toxic raw materials, and its extensive R&D programme has also developed specialised recycling polymer additives which increases the strength of recycled blends and plastic products whilst also reducing plastic waste by between 40 and 50 per cent.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRVKLFLXVLFBBD
12
Date   Source Headline
14th Jan 20257:00 amRNSChange of Name to Solvonis Therapeutics plc
6th Jan 20252:27 pmRNSResult of General Meeting and change of name
16th Dec 20247:00 amRNSProposed acquisition of Awakn Life Sciences Corp
11th Dec 20247:00 amRNSInitial Results University of Nottingham
3rd Dec 20249:44 amRNSNotice of GM and proposed name change
15th Oct 20247:00 amRNSResearch Agreement
4th Oct 20247:00 amRNSResearch and development update
26th Sep 20247:00 amRNSDirectorate Change and grant of options
13th Sep 20247:00 amRNSHalf-year Report
28th Aug 20247:00 amRNSCommercial Collaboration Progress Update
13th Aug 20247:00 amRNSHolding(s) in Company
12th Aug 202410:21 amRNSDirectorate Change
8th Aug 202410:08 amRNSHolding(s) in Company
1st Aug 20247:00 amRNSDirectorate Change
31st Jul 20245:00 pmRNSTotal Voting Rights
23rd Jul 20241:59 pmRNSHolding(s) in Company
23rd Jul 20247:00 amRNSCommercial Collaboration
18th Jul 20247:00 amRNSCommercial Collaboration
17th Jul 20249:28 amRNSHolding(s) in Company
15th Jul 20247:00 amRNSDirectorate Change
12th Jul 20247:00 amRNSHolding(s) in Company
12th Jul 20247:00 amRNSHolding(s) in Company
11th Jul 20249:36 amRNSHolding(s) in Company
11th Jul 20249:27 amRNSHolding(s) in Company
11th Jul 20249:26 amRNSHolding(s) in Company
11th Jul 20249:20 amRNSHolding(s) in Company
11th Jul 20249:20 amRNSHolding(s) in Company
11th Jul 20247:00 amRNSPatent Filings
10th Jul 20244:24 pmRNSHolding(s) in Company
10th Jul 20248:10 amRNSAdmission & Director/PDMR Shareholding
3rd Jul 20242:29 pmRNSPublication of a Prospectus
28th Jun 202412:58 pmRNSResult of AGM
7th Jun 20247:00 amRNSBusiness Update
4th Jun 20244:26 pmRNSNotice of AGM
31st May 20247:00 amRNSPatent Application
28th May 20247:00 amRNSRegulatory Application
9th May 20247:00 amRNSUpdate on recent developments
7th May 20247:00 amRNSGrant of Haemostatic Hydrogel Patent
3rd May 20247:00 amRNSDivestment of Graft Polymer d.o.o – Slo facility
2nd May 20247:00 amRNSReplacement of Chief Executive Officer
30th Apr 20245:05 pmRNSAnnual Financial Report
23rd Apr 20244:17 pmRNSLoan facility update
15th Mar 20247:00 amRNSChairman & Directorate Change & Financial Update
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSGM Statement
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSDirector/PDMR Shareholding
8th Jan 20245:00 pmRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.